A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is a key ...

Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and ...

TrumpRx taps GoodRx discounted drug pricing to offer patients up to 85% savings on Pfizer and other brand-name medications.

Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Pfizer, the biggest U.S.-based drugmaker, is increasing its financial assistance to patients, doubling the allowable income level for people to receive dozens of Pfizer medicines for free. The move ...

Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels.

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...